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Abstract 
Background: Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment 
of high‑risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for 
intensive chemotherapy and/or allogeneic stem cell transplantation. However, response rates to HMA are low and 
there is an unmet need in finding prognostic and predictive biomarkers of treatment response and overall survival. 
We performed global methylation analysis of 75 patients with high‑risk MDS and secondary AML who were included 
in CETLAM SMD‑09 protocol, in which patients received HMA or intensive treatment according to age, comorbidities 
and cytogenetic.
Results: Unsupervised analysis of global methylation pattern at diagnosis did not allow patients to be differenti‑
ated according to the cytological subtype, cytogenetic groups, treatment response or patient outcome. However, 
after a supervised analysis we found a methylation signature defined by 200 probes, which allowed differentiating 
between patients responding and non‑responding to azacitidine (AZA) treatment and a different methylation pattern 
also defined by 200 probes that allowed to differentiate patients according to their survival. On studying follow‑up 
samples, we confirmed that AZA decreases global DNA methylation, but in our cohort the degree of methylation 
decrease did not correlate with the type of response. The methylation signature detected at diagnosis was not useful 
in treated samples to distinguish patients who were going to relapse or progress.
Conclusions: Our findings suggest that in a subset of specific CpGs, altered DNA methylation patterns at diagnosis 
may be useful as a biomarker for predicting AZA response and survival.
Keywords: Myelodysplastic syndromes, Secondary acute myeloid leukemia, DNA methylation, Hypomethylating 
agents, Epigenetic drugs, Prognostic factors, Azacitidine
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
The term epigenetics refers to all the information trans-
mitted through cell division that is not encoded in the 
DNA sequence. The methylation of DNA, encodes some 
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epigenetic information related to the transcriptional 
state of genes [1]. DNA methylation is catalyzed by DNA 
methyltransferases (DNMTs) that transfer a methyl 
group to a cytosine residue (5-methylcytosine) within 
a CpG dinucleotide. The large majority of CpGs in the 
genome are methylated and contribute to stable repres-
sion of repeated sequences in heterochromatin stability 
[2]. Regions enriched in CpG, called CpG islands, are also 
found in the promoters of genes. The majority of these 
CpG islands are unmethylated in cells of normal tissues 
regardless of their differentiation state [1]. This lack of 
methylation in promoter-associated CpG islands allows 
gene expression, if the appropriate transcription factors 
are present and the chromatin structure allows access to 
them [3, 4]. Many human diseases, and in particular can-
cers, are associated with aberrations in the DNA meth-
ylation profile [1, 5–7]. Neoplastic cells frequently display 
global DNA hypomethylation with localized hypermeth-
ylation of CpG islands [4]. Hypomethylation may play a 
role in carcinogenesis through activation of oncogenes 
[8] and chromosomal instability [9]. In contrast, aber-
rant hypermethylation of CpG islands in cancer is clearly 
associated with gene silencing and contributes to the 
inactivation of tumor suppressor genes [4, 10, 11]. Bay-
lin and Jones estimated that the inactivation of tumor 
suppressor genes by gaining DNA methylation occurs as 
often as their inactivation by mutations [7, 12]. In con-
trast to genetic alterations, epigenetic changes are poten-
tially reversible by pharmacological inhibition of DNA 
methylation and histone deacetylation [13], thus provid-
ing a potential point for therapeutic intervention.
The azanucleosides, azacitidine (AZA) and decitabine, 
are incorporated as analog of cytidine into DNA and 
inhibit DNA methyltransferase through covalent binding 
[14]. As a consequence of this function azanucleosides 
are commonly referred to as hypomethylating agents 
(HMAs).
The reactivation of abnormally silenced tumor suppres-
sor genes, DNA repair genes, and microRNAs was long 
thought to be the main mechanism by which HMA exerts 
anti-tumor activity [15–17]. However, more recently, 
HMA have shown to up regulate endogenous retrovirus 
transcripts, which form cytoplasmic double-stranded 
RNA and trigger autonomous and immune-cell induced 
cell death [18–20]. In addition, azanucleosides induce 
cytotoxic effects by impacting on DNA and, in the case of 
AZA also RNA, metabolism [21, 22].
Myelodysplastic syndromes (MDS) refer to a het-
erogeneous group of aging-related myeloid neoplasms 
originating in hematopoietic stem and progenitor cells. 
MDS are characterized by ineffective hematopoiesis and 
increased risk of progression to secondary acute mye-
loid leukemia (sAML). Genetic and epigenetic changes 
contribute to the pathogenesis of the diseases [15, 23–
27]. In the context of epigenetics, altered DNA methyla-
tion patterns have been observed in MDS. In particular, 
the hypermethylation of CpG islands and the silencing of 
linked genes appear in early stages of the disease and are 
associated with poor prognosis and disease progression 
[28–30]. Azacitidine has been shown to prolong overall 
survival compared with conventional care regimens and 
thus, it is recommended as first-line treatment for most 
patients with higher-risk MDS which are not eligible for 
allogeneic stem cell transplantation [14, 31]. Half of the 
patients do not respond favorably to the treatment and 
virtually all responders eventually relapse [32]. A major 
limitation for the clinical management is that several 
months of treatment are required before the efficacy of 
the therapy can be assessed. At present, we lack a robust 
biomarker for predicting treatment response. In par-
ticular, there is debate about the informative potential of 
DNA methylation at diagnosis. Some studies have shown 
an association between pretreatment DNA methylation 
profiles and response to HMA [33, 34], while others have 
not [35–37].
While HMAs are undoubtedly helpful in the treatment 
of MDS patients, there is an urgent need to find prog-
nostic and response-predictive biomarkers that could 
determine whether a patient will respond to HMAs. 
This would avoid progression under treatment, the delay 
of other therapeutical options and the development of 
unwanted side effects. To address this need, the aim of 
our study was to assess DNA methylation patterns at 
diagnosis and follow-up in patients with high-risk MDS 
and sAML and determine if there is a methylation pro-
file that distinguishes patients according to treatment 
response and overall survival (OS).
Results
Patient and sample characteristics
This study included a total of 75 patients with high 
risk MDS or sAML. The main clinical and hemato-
logical characteristics of these patients at diagnosis are 
described in Table 1.
We analyzed 156 bone marrow aspirates that were col-
lected at diagnosis and during follow-up. Of these sam-
ples, 108 were from high-risk MDS and 48 from sAML 
patients. The number of samples at diagnosis and follow-
up are shown in Additional file 1: Table 1. In two patients 
follow-up samples were available, but a sample at diag-
nosis was lacking. Approximately half of all the patients 
received AZA treatment, while the other half under-
went intensive chemotherapy followed or not by ASCT. 
Treatment response to AZA was assessed following the 
criteria defined by the 2006 IWG for MDS patients [38]. 
Based on these criteria, our study included 21 responders 
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Table 1 Main clinical and hematological characteristics of patients at diagnosis (n =75)
Variable Median (range) N (%) (n = 75)
Age, years 66 (32–83)
 < 65 34
 ≥ 65 41
Gender
 Male 52 (69)
 Female 23 (31)
Hemoglobin level, g/L 91 (57–136)
 < 100 50
 ≥ 100 25
Leukocyte count,  × 109/L 2.9 (0.8–108)
 < 4 47
 > 4 and < 11 14
 ≥ 11 14
Platelet count,  × 109/L 68 (5–536)
 < 100 48
 ≥ 100 27
Neutrophil count,  × 109/L 1.23 (0.09–13.55)
 < 0.8 27
 ≥ 0.8 47
 No data 1
Blasts in PB, % 0 (0–74)
 < 5 55
 ≥ 5 20
Blasts in BM, % 15 (0–92)
 < 20 49
 ≥ 20 26
Cytogenetic
 Normal karyotype 28
 Abnormal karyotype 45
 Uninformative CC 2
Cytogenetic category (IPSS‑R)




 Very poor 16
 Uninformative CC 2




 No data 1




 Very high 21
 No data 2
Treatment
 AZA 38
 Other treatment (ICE plus AZA and/or ASCT) 37
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and 16 non responders to AZA treatment. The median 
follow-up of the patients was 12  months, ranging from 
0 to 72  months. Additional file  1: Table  2 summarizes 
the number of patients according to the response to all 
treatments.
The median (OS) of the whole series (75 patients) was 
12.6 months (95% CI 8.4, 16.7), but analysing it accord-
ing to treatment type, we observed that median OS in 
patients that received AZA (n =38) and other treatment 
(n =37) was 12 months (range 7.8–16.2) and 12.6 months 
(range 3–22.1), respectively. Regarding progression free 
survival (PFS), for the entire cohort was 10.4  months 
(95% CI 8.8, 11.9), and analysing by treatment type, 
the median PFS for patients that received AZA was 
10.4 months (range 8.3–12.4), whereas it was 9.5 months 
(range 6.4–12.6) for patients that received other treat-
ment (Additional file  1: Figure  1). No significant dif-
ferences in survival were seen between patients who 
received AZA and those who received other treatment.
Global genome‑wide methylation analysis of bone marrow 
distinguishes healthy controls from the heterogeneous 
group of high risk MDS and sAML patients
Bone marrow aspirates were routinely collected dur-
ing the MDS and sAML diagnostic process. Here, we 
analyzed global genome-wide methylation profile from 
156 samples from patients and ten hematopoietic stem 
cell donors as healthy controls. Given that the controls 
were related donors their median aged (50  years; range 
28–63  years) were younger than patients age (median: 
66 years; range 32–83 years). Specifically, we determined 
the methylation level of 450,000 CpG sites using the Illu-
mina Infinium array platform. We analyzed samples in 
different batches and included the same two reference 
samples to control for potential batch effects. Impor-
tantly, the methylation profiles of these two samples were 
always the same, and all samples fulfilled the trial qual-
ity control criteria. Unsupervised analysis of diagnostic 
samples by principal component analysis segregated neo-
plastic samples from healthy control samples, showing 
homogeneity in the controls and the heterogeneity of the 
neoplastic samples at diagnosis (Fig. 1a). High-risk MDS 
and sAML samples did not separate but were intermixed, 
reflecting the relationship of the two diseases and their 
intrinsic heterogeneity (Fig. 1a). Furthermore, we did not 
observe segregation according to cytogenetic group or 
treatment response at this global level of analysis (data 
not shown).
To identify changes in the DNA methylation profile 
associated with disease, we compared the DNA methyla-
tion patterns from high risk MDS and sAML patients at 
diagnosis (n =73; 48 MDS and 25 sAML) with those from 
healthy controls (n =10). Statistical analysis identified 
40,395 probes that indicated significantly differentially 
methylated sites between the two groups (P < 0.05). To be 
more restrictive, we focused on sites that had an absolute 
mean differential methylation between the two groups 
greater than 0.2, with 0 being un-methylated and 1 being 
fully methylated (> 0.2 methylation difference, P < 0.05). 
Up to 8,247 probes met these criteria. Of these, 6,841 
probes were more methylated in patient samples than 
in healthy controls, and 1,406 probes were less methyl-
ated in patients (Fig. 1b). To better understand the differ-
ences between patients and healthy controls, we focused 
our studies on probes that were located in the promoter 
region, defined from − 2000 to + 500 bp from the tran-
scription start site (TSS). Following the trend of all differ-
entially methylated sites, hypermethylated sites in gene 
promoters were more frequent than hypomethylated. 
Specifically, 1213 gene promoters had at least one CpG 
site more methylated in MDS and sAML patients than in 
healthy controls, while 352 gene promoters showed the 
opposite. Focusing on the predominant hypermethyla-
tion of neoplastic samples, we found that in 109 genes at 
least four sites were more methylated in their promoter 
region. Gene Ontology (GO) of pathways analysis indi-
cated an enrichment of genes related to cadherin and 
Wnt signaling pathways (for more information see Addi-
tional file 1: Figure 2). Taken together, these results fur-
ther substantiate previous studies showing that DNA 
methylation profiles are altered in high-risk MDS and 
sAML samples.
A methylation signature at diagnosis predicts AZA 
response
Taking into account the partial response of patients 
to AZA, response-predicting biomarkers are urgently 
needed. In order to identify a potential biomarker, we 
focused on the 37 patients treated with AZA in our 
cohort from whom a sample was available at diagno-
sis. Of these patients, 21 favorably responded to the 
treatment, and 16 were resistant and did not respond. 
Comparing the two groups, we identified a methylation 
signature, defined by 200 probes that allowed differen-
tiation. When we performed hierarchical clustering with 
the values of these 200 probes, we classified patients into 
two major clusters (Fig. 2). Cluster I included exclusively 
Table 1 (continued)
PB peripheral blood, BM bone marrow, Uninformative CC cases with no metaphases, IPSS International Prognostic Score System, IPSS-R Revised IPSS, WHO World 
Health Organization, AZA azacitidine, ICE idarubicin, cytarabine and etoposide, ASCT allogeneic stem cell transplantation
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Fig. 1 DNA methylation profiles distinguish patients and healthy controls. a Principal component analysis shows a separation between patient and 
control samples after unsupervised analysis. We have analyzed a total of 25 bone marrow samples taken at diagnosis from patients with secondary 
acute myeloid leukemia (sAML) and 48 from patients with myelodysplastic syndrome (MDS). b Heatmap showing major methylation in neoplastic 
samples compared to healthy controls
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responders plus control samples. The second large clus-
ter was further subdivided into clusters II and III. Cluster 
II was mixed and contained patients responding or not 
to AZA while cluster III included only non-responder 
patients.
To better understand the differences between respond-
ers and non-responders, we studied the probes that were 
located in the promoter. We observed that 61 probes 
were inside a gene promoter and 58/61 probes were more 
methylated in responders, whereas only 3/61 probes 
were less methylated in responder patients. Although 
the differences between most probes were not significant 
enough (the average methylation between two groups 
ranged from 0.009 to 0.226), we focused on those with 
differences greater than 0.2. These probes affected 4 
genes CRADD, RDH13, BRDT and PACRG . Only the 
probe in the PACRG gene promoter was hypermethyl-
ated (mean methylation = 0.759) in responders, being the 
β-value methylation nearly to 0.5 in non-responders. The 
three other genes (CRADD, RDH13 and BRDT) showed 
a β-value methylation in responders nearly to 0.47 and 
hypomethylation in non-responder patients (mean meth-
ylation = 0.2666). It is important to note that the RDH13 
gene had five probes in the promoter region, and all were 
less methylated in non-responder (mean methylation = 
0.3644) than in AZA-responder patients (mean methyla-
tion = 0.5564).
In conclusion, DNA methylation of a panel of spe-
cific sites allows distinguishing responders from non-
responders and is possibly related to biological relevant 
gene regulation.
A methylation signature at diagnosis predicts longer 
survival
In order to identify a potential biomarker for OS, we 
focused on the 37 patients with sample available that 
received AZA. There were 19 patients who did not reach 
the median OS (shorter survival) and 18 that exceed 
the median OS (longer survival). Comparing the two 
groups with the combined rank analysis, we obtained a 
Fig. 2 Methylation profile of 200 probes at diagnosis allow distinguishing responders and non‑responders to azacitidine (AZA) treatment. Heatmap 
showing the hierarchical clusterization of the 200 probes obtained with combined rank analysis that are differentially methylated between 
responders and non‑responders in bone marrow samples at diagnosis. Selected genes associated with differentially methylated CpGs are indicated
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methylation signature defined by 200 probes that allowed 
the differentiation between both groups. When we per-
formed hierarchical clustering with the values of these 
200 probes, we classified patients into two major clus-
ters (Fig.  3). Cluster I included exclusively shorter sur-
vival patients and cluster II was mixed and contained all 
patients with longer survival plus 3 patients with shorter 
survival. We also observed that the majority of patients 
with longer survival responded to treatment. To better 
understand the differences between longer and shorter 
survival groups, we studied the probes that were located 
in promoter zones. We observed that 73 probes were 
inside a gene promoter, and there were 3 genes (CPT1C, 
PRRT1 and LYPD3) that had more than two probes 
differentially methylated between the two groups. All 
probes were more methylated in shorter survival patients 
(Additional file 1: Figure 3).
In conclusion, the methylation state of specific CpG 
sites at diagnosis allows identifying those patients with 
longer survival.
Global methylation studies in follow‑up samples did 
not allow predicting which patients would relapse 
or progress
Using the follow-up samples available, we wanted to see 
if the methylation profile described at diagnosis that dis-
tinguished responding from non-responding patients 
was able to differentiate patients who would relapse 
Fig. 3 Methylation profile of 200 probes at diagnosis predict overall survival in AZA treated patients. Heatmap showing the hierarchical 
clusterization of the 200 probes obtained with combined rank analysis that are differentially methylated between longer and shorter survivals in 
bone marrow samples at diagnosis. Selected genes associated with differentially methylated CpGs are indicated
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or progress during follow-up. Our cohort included 50 
follow-up samples of AZA-treated patients. Of these, 
26 samples were from responder patients, 21 were from 
patients non-responders (12 in disease progression) and 
3 samples had no clinical information related to response 
status.
Hierarchical clustering analysis showed strong clusteri-
zation based on patient identity (that means, sequential 
sample from the same patient were more likely to cluster 
together) rather than cytological group or treatment cate-
gory. We observed a decrease in global methylation in the 
follow-up samples after AZA treatment. This genome-
wide demethylation observed after treatment was seen 
both in responding and non-responding patients, but it 
was not observed in patients who received ICE without 
any demethylating agent, demonstrating the demethyla-
tion capacity of AZA treatment (data not shown).
First, we wished to test if at that time of disease pro-
gression after initial response the methylation pattern 
would be similar to that of non-responders at diagnosis. 
For this purpose we used the same 200 CpG probes from 
Fig. 2 to compare samples at disease progression (n =12) 
with diagnostic samples from non-responders (n =16) 
and initial responders (n =21). As shown in Fig.  4, we 
were unable to observe any clear pattern, suggesting that 
initial and acquired resistances have diverse mechanisms 
reflected in diverse methylation patterns.
Second, we compared the differences between patients 
that remained in response after six or more cycles of 
AZA (n =9) and patients who, having responded at some 
point, had progressed to AML (n =7) but all of them had 
received at least 6 AZA cycles (Fig.  5). Again using the 
same 200 CpG probes, we were unable to distinguish 
continuous responders from progressors.
In summary, we identified a methylation profile that 
allowed distinguishing responder and non-responder 
patients at diagnosis, but the same methylation sites were 
not informative of duration of response or disease pro-
gression at follow-up.
Discussion
Aberrant DNA methylation plays an essential role in 
hematopoietic malignancies such as MDS and AML. It 
has been described that MDS blasts have high rates of 
mutations in epigenetic modifiers and exhibit altered 
DNA methylation patterns [39]. Promoter methylation 
has shown to have a significant role in the pathogen-
esis and progression of MDS, but a reliable methylation 
marker, predictive of treatment response has not yet been 
identified. In this study, we wanted to better understand 
Fig. 4 Methylation pattern at time of disease progression after initial response is not similar to methylation pattern from those patients that have 
never respond (non‑responders). Heatmap showing the hierarchical clusterization of samples from patients in progression (n =12) in comparison 
with responder (n =21) and non‑responder (n =16) patients at diagnosis based on DNA methylation of the sites identified in Fig. 2
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the DNA methylation pattern at diagnosis and follow-up 
in patients with high-risk MDS and sAML. In particular, 
we wished to determine if DNA methylation would allow 
predicting initial response to AZA at diagnosis and the 
durability of treatment response and progression.
The effectiveness of HMA in myeloid malignancies 
could be associated with the fact that hundreds of genes 
are often hypermethylated in MDS, and that the level of 
hypermethylation across the genome is linked to poor 
prognosis and a high likelihood of MDS to transform 
to AML as well as AML relapse [28, 36, 40, 41]. In our 
cohort, we observed that high-risk MDS and sAML 
patients had a different methylation pattern at diagnosis 
compared to healthy controls, but we found no differ-
ences in global genome-wide methylation at diagnosis 
according to cytological group (MDS versus sAML), 
cytogenetic groups, type of response to treatment or OS. 
However, the difference between controls and patients at 
diagnosis could be influenced by age differences between 
both groups.
Some years ago Shen et  al. [36] described that the 
decrease in methylation during treatment, rather than 
methylation at the baseline level, might predict the out-
comes of HMA therapy. Similarly, Follo et al. [37] dem-
onstrated that not only was the PI-PLCbeta1 promoter 
hypermethylated in high-risk MDS patients, but also the 
amount of PI-PLCbeta1 mRNA during treatment could 
predict the clinical response to AZA. Conversely, when 
we performed a combined rank analysis, we observed a 
specific methylation pattern at diagnosis, defined by 200 
probes that could predict which patients would respond 
to AZA but we did not find any differences in a decrease 
of methylation during treatment between responding and 
non-responding patients. In the same way, Meldi et  al. 
[33] identified 167 differentially methylated regions of 
DNA at baseline in chronic myelomonocytic leukemia 
that distinguished responders from nonresponders to 
decitabine, and Voso et al. [34] described that BCL2L10 
methylation at diagnosis may predict response to AZA in 
MDS patients.
Fig. 5 Differential methylation associated with initial response does not provide information on response duration or progression. Heatmap 
showing the hierarchical clusterization of samples of response after more than 6 AZA cycles (n =9) and samples of progression (n =7) using the 
methylation status of CpG sites identified in Fig. 2
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From our study at diagnosis we observed that four 
genes (CRADD, RDH13, BRDT and PACRG ) were dif-
ferentially methylated between responding and non-
responding patients to AZA treatment making it of 
interest to study these genes more in depth. There is 
scarce information about these genes associated to high-
risk MDS or sAML, but RDH13 seems to be important 
since it was the only gene with which five probes meth-
ylated differently between the two groups. This gene 
encodes a mitochondrial short-chain dehydrogenase/
reductase, which catalyzes the reduction and oxida-
tion of retinoids. The encoded enzyme may function in 
retinoic acid production and may also protect the mito-
chondria against oxidative stress. Retinol (vitamin A) 
is strictly provided by nutrition, and the active retinol 
product is retinoic acid (RA) which plays a great role 
as a modulator of proliferation and differentiation in 
numerous tissues [42]. Retinoic acid receptors (RARs) 
mediate transcription of different sets of genes con-
trolling differentiation of a variety of cell types, thus 
the target genes regulated depend upon the target cells 
[43]. RDH13 exhibits a wide tissue distribution and, by 
contrast with other members of the RDH11-like group 
of short-chain dehydrogenases⁄reductases, it is a mito-
chondrial rather than a microsomal protein. This protein 
has a greater catalytic efficiency in the reductive than in 
the oxidative direction [44]. In our study we found that 
patients not responding to AZA showed hypomethyla-
tion in the RDH13 promoter, and therefore, we speculate 
that RDH13 overexpression might cause deregulation 
of specific genes managed by RA, involving a change 
in the expression of other genes that could be related 
to the lack of response to AZA treatment, but as far as 
we know, there is no data in the literature that supports 
our hypothesis. At the same time, the PACRG gene also 
seemed interesting, as its promoter was hypermethyl-
ated in responding patients, while this gene promoter in 
non-responding patients showed a methylation β-value 
next to 0.5. The PACRG gene encodes a protein that 
forms a large molecular complex with chaperones. It has 
recently been described that the PACRG protein plays 
an important role in tumor necrosis factor (TNF) sign-
aling, and this function of PACRG in positively regulat-
ing TNF signaling may help to explain the association of 
PACRG polymorphisms with increased susceptibility to 
intracellular pathogens [45]. Agirre et al. [46] studied the 
role of promoter hypermethylation in the regulation of 
PACRG expression in different tumour cell lines and pri-
mary patient samples and demonstrated that abnormal 
methylation resulted in downregulation of PACRG gene 
expression. Although, they focused on different diseases, 
we can hypothesize that the degree of hypermethylation 
in responding patients may be explained by the decrease 
in PACRG gene expression, that could be reverted with 
AZA treatment.
This means that two of the genes detected with a dif-
ferential methylation signature between responding and 
non-responding patients to AZA, have a protective func-
tion; RDH13 against oxidative stress and PACRG against 
infections. This suggests that the ability of the cell to cope 
with stress could be related to the ability of treatment 
response. Despite the limited size of our cohort and the 
need for an independent validation cohort, we believe 
that this profile could be a good tool for future targeted 
methylation studies.
In 2010, Shen et al. [36] analyzed 317 samples of MDS 
patients and concluded that DNA methylation of some 
specific genes predicts OS and PFS in MDS. To be more 
precise, patients with high methylation levels in ten genes 
(CFH1, CDH13, ERα, NOR1, NPM2, OLIG2, p15, PGRA 
, PGRB, RIL) had shorter OS and worse PFS. In line with 
this article, our study defined a panel of 200 probes that 
correlated a differential methylation pattern at diagno-
sis according to patients’ survival. Within these probes, 
there were three genes, CPT1C, PRRT1 and LYPD3, of 
special interest. Patients with shorter survival had their 
promoters more methylated than patients with longer 
survival. To our knowledge, the impact of methylation 
in these genes in OS has not been reported in the litera-
ture, but other findings have been described. CPT1C is 
expressed predominantly in mammalian brain and Casals 
et  al. [47] described that CPT1C is highly expressed in 
certain virulent tumor cells, conferring them resistance 
to glucose-and oxygen-deprivation and therefore, CPT1C 
may be a promising target in the treatment of cancer. 
PRRT1 is a 2-pass transmembrane protein belonging to 
the CD225/Dispanin family and is a component of the 
outer of AMPAR complex (ionotropic transmembrane 
receptor for glutamate that mediates fast synaptic trans-
mission in the central nervous system). The proteins of 
the inner and outer core serve as a platform for other, 
more peripherally associated AMPAR constituents. 
Alone or in combination, these auxiliary subunits control 
the gating and pharmacology of the AMPAR complex 
and profoundly impact their biogenesis and protein pro-
cessing [48]. Zhang C et  al. [49] describes in their arti-
cle PRRT1 as a biomarker of high risk group in breast 
cancer according to their DNA methylation correlation 
network. LYPD3 is a protein that supports cell migra-
tion and may be involved in tumor progression [50]. 
Gruet et  al. [51] described that LYPD3 mRNA expres-
sion levels were low in normal tissues, but there is a sig-
nificant (P < 0.001) over-expression of LYPD3 in several 
malignant tissues (breast cancer, cervical squamous cell 
carcinoma and endocervical adenocarcinoma, lung ade-
nocarcinoma, lung squamous cell carcinoma, pancreatic 
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adenocarcinoma, testicular germ cell tumors and thy-
moma). This suggests that LYPD3 could be a potential 
therapeutic target in multiple different cancers. Although 
all the information found in literature about these genes 
is referred to solid tumors they could also be of interest 
for MDS and sAML.
It has also been described that methylation changes 
in specific genes contribute to disease pathogenesis and 
may be useful as a marker to monitor the treatment 
efficacy [52]. Regarding changes in global methylation 
during treatment, we observed that there is a strong clus-
tering based on patient identity rather than treatment 
response, as we observed that demethylation occurs in 
both, responding and non-responding patients. Further-
more, the methylation profile at diagnosis which helped 
to distinguish responding from non-responding patients 
was not useful in treated samples (at follow-up). Thus, 
our hypothesis that the methylation profile at relapse or 
progression returns to stages similar to those observed 
at diagnosis in non-responding patients, was not dem-
onstrated, suggesting that the mechanisms that affect 
relapse/progression of the disease are different from 
those that predict response at diagnosis.
Aberrant DNA methylation patterns that lead to tran-
scriptional silencing have been recognized as a key 
epigenetic mechanism in the process of malignant trans-
formation. Although our results are in line with other 
studies reported in the literature regarding the impor-
tance of studying aberrant DNA methylation in MDS 
and sAML patients, a validation of our findings in longer 
cohorts would be of interest. In parallel, it would be 
interesting to assess the functional contribution of dif-
ferentially methylated genes to provide novel targets for 
combinatorial therapies to enhance AZA response and to 
improve OS.
Conclusions
In summary, in this study we defined a methylation 
signature at diagnosis that allows the identification of 
responding and not responding patients to AZA treat-
ment and also another methylation profile that identifies 
patients with longer survival. This is an important step 
towards the development of an urgently needed predic-
tive tool for AZA response.
Methods
Patients
Bone marrow aspirates from 75 patients with high-risk 
MDS and sAML were obtained at baseline and during 
follow-up from 2009 to 2016 (Additional file 1: Table 1). 
All samples were collected as part of the SMD-09 proto-
col from the CETLAM Group, a prospective multicenter 
study. The study was approved by the Institut Català 
d’Oncologia - Hospital Germans Trias i Pujol Ethics 
Committee and the Scientific Committee of the CET-
LAM group. Informed consent was obtained from each 
patient in accordance with the Declaration of Helsinki. 
Ten healthy hematopoietic stem cell related donors were 
also included as normal controls for DNA methylation 
profiles.
In this protocol patients were classified according to 
age and comorbidities to determine whether or not they 
were candidates for intensive treatment. Patients fit for 
intensive treatment were also stratified according to 
cytogenetic (Additional file  1: Figure  4). Treatments in 
the CETLAM SMD-09 protocol included AZA, inten-
sive chemotherapy (idarubicin, cytarabine and etoposide, 
ICE) and/or allogeneic stem cell transplantation (ASCT) 
(Additional file 1: Figure 4). We calculated the IPSS and 
IPSS-R values only for MDS patients, as these prognostic 
models are specific for this type of patients.
Response criteria
For response criteria we used the definitions estab-
lished by the 2006 International Working Group (IWG) 
for MDS patients [38]. Briefly, patients who achieved 
complete remission, bone marrow complete remission, 
partial remission or hematological improvement were 
considered to be on response. The remaining situations 
were considered as no response. Response to AZA was 
assessed, when possible, after cycle 3, 6, 9 and 12 and 
response to chemotherapy was assessed after cycle 1 or 2.
Cytogenetic
Conventional G-banding cytogenetic (CC) was per-
formed in bone marrow samples at diagnosis following 
standard procedures. Karyotypes were described accord-
ing to the International System for Human Cytogenetic 
Nomenclature [53].
DNA samples
Whole bone marrow samples were collected at diagno-
sis (n =73) and at follow-up (n =83). Genomic DNA was 
extracted from the 156 samples (75 patients) and from 
10 samples from healthy donors using the QIAamp DNA 
Blood Mini Kit (Qiagen, Werfen). One microgram of 
DNA was modified with sodium bisulfate using the EZ 
DNA methylation kit (Zymo Research, Ecogen) accord-
ing to the manufacturer’s instructions.
Methylation array and statistical analysis
Bisulfite converted DNA was then processed and 
hybridized to the Infinium Human Methylation 450  K 
BeadChip from Illumina, according to the manufac-
turer’s recommendations. The 450  K DNA Methyla-
tion array assesses the methylation status of 485,764 
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cytosines distributed over the whole genome, which 
correspond to CpG dinucleotides (99.3%) and CNG 
targets (0.7%) [54]. According to their associated RNA 
transcripts, 361,766 CpGs (74.4%) correspond to clas-
sic coding messenger RNA genes, 4,168 (0.85%) are 
linked to non-coding RNAs (microRNAs and long non-
coding RNAs), and for 119,830 (24.6%) sites there are 
no annotated transcripts associated with the described 
CpG location [54]. Fluorescence signals generated for 
unmethylated and methylated cytosines were trans-
formed into a beta-value (β-value) ratio ranging from 0 
(completely unmethylated site) to 1 (completely meth-
ylated site). Methylation data are available at the Gene 
Expression Omnibus (GEO) database under accession 
number GSE152710. Raw IDAT files from Infinium 
450  K experiments were imported into RnBeads for 
DNA methylation analysis, including quality control, 
data preprocessing and normalization [55]. The meth-
ylation β-values were normalized using the BMIQ nor-
malization method [56]. RnBead was used to perform 
unsupervised principal component analysis (PCA) and 
to explore associations among traits [55]. Differential 
methylation analysis was conducted at a site and region 
level according to the specified sample groups. P val-
ues of the site level were computed using the limma 
package [57]. Differential methylation at the site level 
was computed based on a variety of metrics: (a) com-
parison of the difference in mean methylation levels 
of the two groups; (b) the quotient in mean methyla-
tion; and c) a statistical test (limma or t test) assess-
ing whether the methylation values in the two groups 
originate from distinct distributions. Additionally, each 
site was assigned a rank based on each of these 3 cri-
teria. A combined rank is computed as the maximum 
(i.e. worst) rank among the three ranks. The smaller the 
combined rank of a site, the more evidence for differ-
ential methylation it exhibits. Differential methylation 
analysis was performed to identify hypermethylated 
and hypomethylated probes between the compared 
groups and was performed according to the combined 
ranking. We analyzed the combined rank among the 
200 best ranking sites. Data shown in map are β-value 
Z-score converted.
DNA methylation data were assessed and statistically 
treated as CpG units (consisting of one or more CpG 
dinucleotides). Treating the region as a unit in the dif-
ferential methylation analysis allows identifying regions 
with consistently coordinated methylation changes. 
Hierarchical clustering was performed using the hclust 
function, with default parameters from the Biocon-
ductor pheatmap package version 1.0.12. All statisti-
cal analyses were performed using RnBeads package 
version 1.8.0. Post-statistical analyses were done using 
in-house R scripts.
Overall Survival and Progression free survival statistical 
analysis
Overall survival (OS) was defined as time from diag-
nosis to the last follow-up or death from any cause and 
progression free survival (PFS) as time from diagnosis to 
progression or death related to disease. Survival curves 
were performed using the Kaplan–Meier method and 
log-rank test was used for comparisons between groups. 
The statistical package SPSS, version 24.0 (SPSS Inc., 
Chicago, IL, USA) was used for all analyses.
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